Connect with us

Published

on

The chief executive of AstraZeneca (AZ) has told Sky News that the company’s decision to begin seeking a modest profit from its COVID vaccine is unlikely to kick in until next year.

Pascal Soriot said this was because it still had many doses of the vaccine to supply that it had promised to do so at cost.

AZ announced earlier this month that it would be seeking to achieve a modest profit in future from the vaccine In order to fund its new anti-viral COVID treatment.

But Mr Soriot stressed that, while some countries would be charged above cost for the vaccine, many more would not.

AstraZeneca. Pic: AP
Image:
The Oxford-AstraZeneca vaccine has been sold at cost since it first became available Pic: AP

He said: “You have to remember that the orders we are taking today will be delivered next year. We still have a lot of orders at no profit to deliver. So they will be delivered next year.

“So you have got to think of the infection as if you were already in next year. And so essentially most of the world at that point will be in a different phase. And we will be more in a regional epidemic or regional pandemic than a global pandemic.

“But you know, we will of course adapt to every circumstance and countries that have low purchasing power we will be supplied at no profit or very low price and others will be a bit more.”

More on Covid-19

Mr Soriot insisted that he had no regrets that AZ had provided the vaccine at cost even though some of its competitors, such as Pfizer and Moderna, have supercharged their profits through charges for their COVID vaccines.

He went on: “We always knew that some vaccines would be sold at a profit and we made the decision from day one that we would partner with Oxford and deliver this vaccine around the world at no profit so everybody could access it much as possible.

Vials of COVID vaccines made by AstraZeneca, Pfizer, Johnson and Johnson, and Sputnik V
Image:
Vials of COVID vaccines made by AstraZeneca, Pfizer, Johnson and Johnson, and Sputnik V

“And again, we’ve delivered more than 2 billion doses, 30% of global supply so far, so it really has worked quite well actually. So we always knew that it was what we were going to do. So there is no surprise, so there can’t be any regret – it was our plan all along.”

He was speaking as AZ, the largest company in the FTSE 100, formally unveils The Discovery Centre, its new £1bn research and development facility in Cambridge, which will be home to some 2,200 scientists.

The centre, to be opened by the Prince of Wales today, represents the biggest single investment ever made by AZ.

It has been specifically sited in Cambridge to be at the heart of the city’s life sciences cluster, within close proximity to the Royal Papworth and Addenbrookes hospitals, Cancer Research UK and the University of Cambridge’s school of clinical medicine.

The site is referred to in scientific circles as the ‘Nobel factory’ as it has created more Nobel Prize winners than anywhere else in the world.

Mr Soriot said AZ spent around $7bn (£5.3bn) on research and development annually – of which “a large proportion”, close to one third, is deployed in the UK.

He added: “it’s a very substantial investment we make each year.”

The opening comes at a hugely busy time for AZ which, earlier this year, completed the $39bn takeover of the rare diseases specialist Alexion.

That took the company, traditionally better known in the industry for its treatments for cancers, heart and respiratory conditions, into a fourth therapy area – and now it has decided, based on the success of its COVID vaccine roll out, to expand into a fifth, vaccines, as well.

However, asked whether AZ was trying to do too much at once, Mr Soriot insisted this was not the case.

He added: “We have great strengths in oncology and we believe we can be one of the three great companies in the world in oncology and maybe even better than that by 2025.

“We continue to do very well in cardiovascular and bio pharmaceuticals overall and now we have rare diseases and vaccines.

“What we call the vaccine and immunotherapy unit is really looking at is managing this portfolio of products to treat or vaccinate people with viral diseases.

“We want to maximise the value of these assets and manage them better.

“Now whether we invest in the long run in this field remains to be seen, but there’s a lot of synergies across this portfolio of products.”

Mr Soriot pointed out that AZ had just achieved its first quarter during which it had notched up $10bn worth of sales.

It is a significant milestone because, when Mr Soriot oversaw AZ’s successful defence against an unwanted takeover approach from Pfizer in 2014, he promised investors that AZ would be delivering annual sales of $40bn a year by 2023.

Continue Reading

Business

Interpath-owner to kick off £900m sale of Claire’s administrator

Published

on

By

Interpath-owner to kick off £900m sale of Claire's administrator

The restructuring firm drafted in to advise Sir Jim Ratcliffe on a radical cost-cutting programme at Manchester United Football Club will this week be put up for sale with a £900m price tag.

Sky News has learnt that advisers to HIG Europe, the majority shareholder in Interpath Advisory, will on Monday begin circulating information about the business to potential buyers.

City insiders said on Sunday that HIG had received a large volume of inbound enquiries from prospective suitors since it emerged that it was in the process of appointing bankers at Moelis to handle an auction.

Blackstone, Bridgepoint, Onex, PAI Partners and Permira are among the buyout firms expected to show an interest in buying Interpath, according to banking sources.

More from Money

Interpath was spun out of KPMG UK in 2021 in a deal triggered by the changing regulatory climate in the audit profession.

Growing concerns over conflicts of interest between accountancy giants’ audit and consulting arms had been exacerbated by the collapse of companies such as BHS and Carillion, prompting a number of disposals by ‘big four’ firms.

Interpath has advised on a string of prominent restructuring and cost-saving mandates for clients, including acting as administrator to the UK and Ireland subsidiaries of Claire’s, the accessories retailer which collapsed during the summer.

Sources said that Interpath had doubled its earnings before interest, tax, depreciation and amortisation since HIG Europe acquired the business four-and-a-half years ago.

It is also said to be on track to record a 20% increase in annual revenues in the current financial year.

A sale of Interpath is expected to be agreed during the first quarter of 2026.

HIG declined to comment.

Continue Reading

Business

Former chancellor Osborne is shock contender to head HSBC

Published

on

By

Former chancellor Osborne is shock contender to head HSBC

George Osborne, the former chancellor, has emerged as a shock contender to become the next chairman of HSBC Holdings, one of the world’s top banking jobs.

Sky News can exclusively reveal that Mr Osborne, who was chancellor from 2010 until 2016, was approached during the summer about becoming the successor to Sir Mark Tucker.

This weekend, City sources said that Mr Osborne was one of three remaining candidates in the frame to take on the chairmanship of the London-headquartered lender.

Naguib Kheraj, the City veteran who was previously finance director of Barclays and deputy chairman of Standard Chartered, is also in contention.

The other candidate is said to be Kevin Sneader, the former McKinsey boss who now works for Goldman Sachs in Asia.

It was unclear this weekend whether other names remained in contention for the job, or whether the board regarded any as the frontrunner at this stage.

Mr Osborne’s inclusion on the shortlist is a major surprise, given his lack of public company chairmanship experience.

More from Money

With a market capitalisation of almost £190bn, HSBC is the second-largest FTSE-100 company, after drugs giant AstraZeneca.

The bank has been looking for a replacement for Sir Mark for nearly a year, but has run what external critics have labelled a chaotic succession process.

Sir Mark, who has returned to the helm of insurer AIA as its non-executive chairman, stepped down at the end of September, but remains an adviser to the board.

Brendan Nelson, the former KPMG vice-chairman, became interim chair of HSBC last month and will remain in place until a permanent successor is found.

If he got the job, Mr Osborne would be a radical choice for one of Britain’s biggest corporate jobs.

Since stepping down as an MP, he has assumed a varied professional life, becoming editor of the London Evening Standard for three years, a post he left in 2020.

Since then, he has become a partner at Robey Warshaw, the merger advisory firm recently acquired by Evercore, where he remains in place.

If he were to become HSBC chairman, he would be obliged to give up that role.

Mr Osborne also chairs the British Museum, is an adviser to the cryptocurrency exchange Coinbase and is chairman of Lingotto Investment Management, which is controlled by Italy’s billionaire Agnelli business dynasty.

During his chancellorship, Mr Osborne and then prime minister David Cameron fostered closer links with Beijing in a bid to boost trade ties between the two countries.

“Of course, there will be ups and downs in the road ahead, but by sticking together we can make this a golden era for the UK-China relationship for many years to come,” he said in a speech in Shanghai in 2015.

Mr Osborne was also reported to have intervened on HSBC’s behalf as it sought to avoid prosecution in the US in 2012 on money laundering charges.

The much cooler current relationship between the UK – and many of its allies – and China will be the most significant geopolitical context faced by Sir Mark’s successor as HSBC chairman.

While there is little doubt about his intellectual bandwidth for the role, it would be rare for such a plum corporate job to go to someone with such a spartan public company boardroom pedigree.

His lack of direct banking experience would also be expected to come under close scrutiny from regulators.

HSBC’s shares have soared over the last year, rising by more than 50%, despite the headwinds posed by President Donald Trump’s sweeping global tariffs regime.

When he was appointed, Mr Tucker became the first outsider to take the post in the bank’s 152-year history – and which has a big presence on the high street thanks to its acquisition of the Midland Bank in 1992.

He oversaw a rapid change of leadership, appointing bank veteran John Flint to replace Stuart Gulliver as chief executive.

The transition did not work out, however, with Mr Tucker deciding to sack Mr Flint after just 18 months.

He was replaced on an interim basis by Noel Quinn in the summer of 2018, with that change becoming permanent in April 2020.

Mr Quinn spent a further four years in the post before deciding to step down, and in July 2024 he was succeeded by Georges Elhedery, a long-serving executive in HSBC’s markets unit and more recently the bank’s chief financial officer.

The new chief’s first big move in the top job was to unveil a sweeping reorganisation of HSBC that sees it reshaped into eastern markets and western markets businesses.

He also decided to merge its commercial and investment banking operations into a single division.

The restructuring, which Mr Elhedery said would “result in a simpler, more dynamic, and agile organisation” has drawn a mixed reaction from analysts, although it has not interrupted a strong run for the stock.

During Sir Mark’s tenure, HSBC continued to exit non-core markets, selling operations in countries such as Canada and France as it sharpened its focus on its Asian operations.

HSBC has been contacted for comment, while Mr Osborne could not be reached for comment.

In late September, HSBC said in a statement: “The process to select the permanent HSBC Group Chair, led by Ann Godbehere, Senior Independent Director, is ongoing.

“The company will provide further updates on this succession process in due course.”

Continue Reading

Business

Direct cost of Jaguar Land Rover cyber attack which impacted UK economic growth revealed

Published

on

By

Direct cost of Jaguar Land Rover cyber attack which impacted UK economic growth revealed

The cyber attack on Jaguar Land Rover (JLR), which halted production for nearly six weeks at its sites, cost the company roughly £200m, it has been revealed.

Latest accounts released on Friday showed “cyber-related costs” were £196m, which does not include the fall in sales.

Profits took a nose dive, falling from nearly £400m (£398m) a year ago to a loss of £485m in the three months to the end of September.

Money blog: Apple launches £220 iPhone ‘sock’ today – fans are divided

Revenues dropped nearly 25% and the effects may continue as the manufacturing halt could slow sales in the final three months of the year, executives said.

The impact of the shutdown also hit factories across the car-making supply chain.

Slowing the UK economy

The production pause was a large contributor to a contraction in UK economic growth in September, official figures showed.

Had car output not fallen 28.6%, the UK economy would have grown by 0.1% during the month. Instead, it fell by 0.1%.

Please use Chrome browser for a more accessible video player

How cyber attack ‘effectively hacked GDP’

Read more from Sky News:
Telegraph future in limbo again as RedBird abandons £500m deal

Reacting to JLR’s impact on the GDP contraction, its chief financial officer, Richard Molyneux, said it was “interesting to hear” and it “goes to reinforce” that JLR is really important in the UK economy.

The company, he said, is the “biggest exporter of goods in the entire country” and the effect on GDP “is a reflection of the success JLR has had in past years”.

Recovery

The company said operations were “pretty much back running as normal” and plants were “at or approaching capacity”.

Production of all luxury vehicles resumed.

Investigations are underway into the attack, with law enforcement in “many jurisdictions” involved, the company said.

When asked about the cause of the hack and the hackers, JLR said it was not in a position to answer questions due to the live investigation.

A run of attacks

The manufacturer was just one of a number of major companies to be seriously impacted by cyber criminals in recent months.

Please use Chrome browser for a more accessible video player

Are we in a cyber attack ‘epidemic’?

High street retailer Marks and Spencer estimated the cost of its IT outage was roughly £136m. The sum only covers the cost of immediate incident systems response and recovery, as well as specialist legal and professional services support.

The Co-Op and Harrods also suffered service disruption caused by cyber attacks.

Four people were arrested by police investigating the incidents.

Continue Reading

Trending